US Stock Market Research

AI Stocks

AI-linked names now account for a disproportionate share of US large-cap index gains, with capital spending on data centers and accelerators still accelerating.

Semiconductor Stocks

The chip cycle has historically been one of the most cyclical corners of the market, but AI-driven demand for advanced logic and high-bandwidth memory has extended the current upcycle well beyond prior norms.

Quantum Computing Stocks

Pure-play quantum names are among the highest-beta, most sentiment-driven stocks in the market, prone to sharp rallies on partnership or milestone news and equally sharp drawdowns when hype cools.

Defense Stocks

Elevated global defense spending, driven by an unsettled geopolitical environment, has kept order backlogs at major contractors near record levels.

Nuclear Energy Stocks

Utility-scale data center power-purchase agreements with nuclear operators have become a recurring catalyst for the group, alongside continued policy support for reactor life extensions and new builds.

Robotics Stocks

Falling sensor and compute costs, paired with AI advances in perception and motion planning, have widened the set of tasks robots can economically automate.

Cybersecurity Stocks

The industry has consolidated around a smaller number of broad security platforms competing to displace point-solution vendors, alongside AI adding both a new attack surface to defend and new tools to defend it with.

Cloud Computing Stocks

AI workloads have become the fastest-growing driver of cloud infrastructure revenue, reshaping how the largest cloud providers allocate capital spending.

Electric Vehicle Stocks

Growth rates across the EV pure-plays have moderated from their earlier hyper-growth phase as the category matures and competition, especially from Chinese manufacturers, intensifies.

Uranium Stocks

Years of underinvestment in new mine supply, paired with rising reactor demand and Western utilities' push to diversify enrichment away from Russian supply, has tightened the uranium supply-demand balance.

Pharmaceutical Stocks

Large-cap pharma pairs steady cash flows from established drugs with pipeline bets, while smaller biotechs trade far more on individual trial readouts and approval decisions.

Technology

Semiconductors

Artificial Intelligence

Cloud Computing

Cybersecurity

Healthcare

Biotechnology

Financials

Insurance

Energy

Industrials

Consumer Discretionary

Consumer Staples

Communication Services

Real Estate